All In MedTech

Device Trial Radar · NCT02187549

Safety and Effectiveness Study of a Non-Crosslinked HA Alkylamide HYADD(TM) 4 Hydrogel for Osteoarthritis of the Knee

Last checked: Nov 19, 2026Latest source record: Oct 5, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 332 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

332

Planned (sponsor's estimate)

Start

Jun 2014

Primary completion

Feb 2016

Study completion Mar 2016

Sponsor

Lead sponsor
Fidia Farmaceutici s.p.a.Not on our public-company list
Sponsor type
Industry
First posted
Jul 11, 2014

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether intra-articular hyaluronic acid provides symptomatic relief of osteoarthritis of the knee.

Conditions

  • Knee Osteoarthritis

Interventions

  • HYMOVISDevice

    Intra-articular injection

  • PlaceboDevice

    Intra-Articular Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Western Ontario and McMaster Universities Osteoarthritis (WOMAC) Pain Sub-scoreTime frame: 26 weeks

Locations

21 sites in 1 country. Site status is shown where the registry gives one.

  • Achieve Clinical Research

    Birmingham, Alabama

  • Alabama Clinical Therapeutics

    Brimingham, Alabama

  • Elite Clinical Studies

    Phoenix, Arizona

18 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.